Active	Status	Sponsor type	Region	Phase	Filter
7 Active 0 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Cousins, Richard
NEBULA, NCT05043714: Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours Initiation of trial in combination with NG-641 Sep 2021 - Sep 2021: Initiation of trial in combination with NG-641	Active, not recruiting	1	30	Europe, US	NG-641 in combination with Nivolumab	Akamis Bio, Bristol-Myers Squibb	Metastatic Cancer, Epithelial Tumor	08/24	12/24
FORTIFY, NCT05165433: Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours	Active, not recruiting	1	198	Europe, US	NG-350A plus Pembrolizumab, KEYTRUDA®	Akamis Bio, Merck Sharp & Dohme LLC	Epithelial Tumor, Metastatic Cancer	03/25	05/25
NCT04161417: Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer	Recruiting	N/A	2500	Europe	Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling	Judith Dixon-Hughes, Cancer Research UK, NHS Greater Glasgow and Clyde	Neoplasms Pancreatic	12/25	12/25
Parkes, Eileen
Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors	Recruiting	1/2	374	Europe, Canada, Japan, US, RoW	Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil	Takeda, Takeda Development Center Americas, Inc. (TDC Americas)	Solid Neoplasms	01/26	01/26
NEBULA, NCT05043714: Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours Initiation of trial in combination with NG-641 Sep 2021 - Sep 2021: Initiation of trial in combination with NG-641	Active, not recruiting	1	30	Europe, US	NG-641 in combination with Nivolumab	Akamis Bio, Bristol-Myers Squibb	Metastatic Cancer, Epithelial Tumor	08/24	12/24
FORTIFY, NCT05165433: Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours	Active, not recruiting	1	198	Europe, US	NG-350A plus Pembrolizumab, KEYTRUDA®	Akamis Bio, Merck Sharp & Dohme LLC	Epithelial Tumor, Metastatic Cancer	03/25	05/25
TARGET National, NCT04723316: Tumour Characterisation to Guide Experimental Targeted Therapy - National	Recruiting	N/A	6000	Europe		The Christie NHS Foundation Trust	Cancer	01/26	01/28